International Biotechnology Trust’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

International Biotechnology Trust’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-130,900	Closed	-$9.29M	–	85
2022 Q1	$9.29M	Sell	130,900 -9,000	-6%	-$1.12M	2.1%	19
2021 Q4	$19.3M	Sell	139,900 -36,500	-21%	-$4.64M	4.3%	6
2021 Q3	$24.5M	Hold	176,400	–	–	5.91%	5
2021 Q2	$17.1M	Hold	176,400	–	–	4.52%	8
2021 Q1	$12.1M	Sell	176,400 -24,000	-12%	-$1.94M	3.19%	13
2020 Q4	$17.2M	Buy	200,400 +63,000	+46%	+$5.34M	4.69%	7
2020 Q3	$8.93M	Buy	137,400 +92,400	+205%	+$6.06M	2.88%	13
2020 Q2	$3.12M	Buy	+45,000	New	+$2.39M	1.04%	23
2019 Q3	–	Sell	-50,949	Closed	-$2.23M	–	66
2019 Q2	$2.23M	Buy	50,949 +20,949	+70%	+$1.18M	0.83%	30
2019 Q1	$1.54M	Buy	+30,000	New	+$1.3M	0.57%	47

Other funds holding BHVN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

International Biotechnology Trust's BHVN Position: Q2 2022 in Review

International Biotechnology Trust sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 130,900 shares — an estimated $9.29M sold.

International Biotechnology Trust first reported a position in BHVN in Q1 2019 and held it in 10 quarters. The position peaked at $24.5M in Q3 2021. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

International Biotechnology Trust reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
International Biotechnology Trust sold 130,900 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $9.29M.
International Biotechnology Trust first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 10 quarters.
International Biotechnology Trust's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $24.5M in Q3 2021.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on International Biotechnology Trust's 13F filing for Q2 2022, filed 16 Aug 2022.